Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Incretin-Based Drugs Market?

In recent times, the market size of incretin-based drugs has seen sturdy growth. With a compound annual growth rate (CAGR) of 7.5%, it’s projected to escalate from $25.89 billion in 2024 to $27.83 billion in 2025. This substantial growth during the historical phase is credited to the worldwide increase in type 2 diabetes instances, the launch of GLP-1 receptor agonists such as exenatide and liraglutide, substantial investments in research and development, favorable regulatory green lights for DPP-4 and GLP-1 drugs, a transition from insulin and sulfonylureas to newer categories of drugs, and the availability of once-weekly injectable formulations.

What Growth Rate Is Forecasted for the Incretin-Based Drugs Market by 2029?

In the forthcoming years, the market for incretin-based drugs is predicted to experience significant growth, with a projected value of $36.7 billion in 2029, corresponding to a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the forecast period is primarily due to factors such as the increased preference for fixed-dose combination therapies, a growing emphasis on weight management and obesity-related diabetes, advancement in personalized medicine and companion diagnostics, rising demand for minimally invasive drug delivery technologies, and an aging population with a greater comorbidity burden. During this forecast period, key trends that are expected to emerge include the incorporation of incretin medications into obesity control protocols, development of dual and triple agonists to boost metabolic outcomes, digital healthcare integration with incretin treatments for personalized supervision, dominance of combination therapy over monotherapy in the management of advanced diabetes, and increased attention towards long-lasting weekly injections to minimize the dosing load.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Which Key Companies Are Shaping the Future of the Incretin-Based Drugs Market?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Which Factors Are Driving Demand in the Incretin-Based Drugs Industry?

An increasing number of type 2 diabetes mellitus cases is predicted to fuel the expansion of the market for incretin-based drugs. Characterized by insulin resistance and failing insulin secretion, type 2 diabetes mellitus is a chronic metabolic disorder that results in increased blood glucose levels. The rise in Type 2 diabetes cases can be attributed to poor dietary habits and lack of physical activity, which lead to insulin resistance and hinder the body’s capacity to control blood sugar levels. Incretin-based medications offer a remedy by amplifying insulin release post meals, reducing the production of glucagon, and assisting in decreasing blood sugar levels. These drugs also slow down digestion, suppress appetite, and by doing so aid in glucose regulation and weight loss. For example, the National Health Service, a UK government department, stated in June 2024 that approximately 549,000 more individuals in England were at risk of developing type 2 diabetes in 2023. This spiked the total number of people with pre-diabetes to over 3.6 million, marking nearly a 20% increase from 2022. Due to these reasons, the increasing occurrence of type 2 diabetes mellitus is contributing to the growth of the incretin-based drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24570&type=smp

How Is the Incretin-Based Drugs Market Segmented by Several Divisions?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide, Albiglutide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

What are the Emerging Market Trends Driving the Growth of the Incretin-Based Drugs Industry?

Key players in the incretin-based drugs market are striving to create generic versions of drugs, aiming to deliver more efficient and patient-centric treatments for type 2 diabetes. A generic drug bears the same active ingredients, strength, method of administration, and dosage form as its branded counterpart, but is marketed by its chemical name instead of a brand. For example, in December 2024, the UK-based Hikma Pharmaceuticals PLC introduced the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the US, following FDA approval. This marked it as a supplementary treatment, along with diet and exercise, to better regulate blood sugar levels in adults and children above 10 years dealing with type 2 diabetes, thereby presenting a cost-effective alternative amidst the ongoing scarcity of GLP-1 medications.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Regions Are Driving Growth in the Incretin-Based Drugs Market?

North America was the largest region in the incretin-based drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24570

This Report Delivers Insight On:

1. How big is the incretin-based drugs market, and how is it changing globally?

2. Who are the major companies in the incretin-based drugs market, and how are they performing?

3. What are the key opportunities and risks in the incretin-based drugs market right now?

4. Which products or customer segments are growing the most in the incretin-based drugs market?

5. What factors are helping or slowing down the growth of the incretin-based drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model